I wasn't trying to say the sale had no value,
it certainly did.
A couple $million is not chump change to Wave, and as noted by RoT, there is no record of Safend products ever having been sold at such scale ... scale is always encouraging.
On a similar note one cannot over emphasize that the Safend segment, according to reporting, operates at a profit. Wave has a rich history of segments, add-ons, and science products that never ever turn a dime.
Safend does, and is beginning to develop a real trend line. There was a valley in sales for a few Qs post aquisition under the old regime, but in the case of that segment, it seems to have turned around (for a few Qs in a row now). Perhaps this is new management. Perhaps the sale at scale is new management. We know that Safend had its hooks into a number of potentially promising areas (notably e.g. the NHS). The Safend segment running as a profitable business can only be a good thing.
The point of my post was that this is NOT the first mover/launch customer/marquee demonstratio/product validation sale that leads to follow-on sales in Wave's core offerings. Zen points out the small govt sale of VSC back in Q2, unfortunately that sale lacks all the features of scale demonstration that the product so desperately needs.
My cat and the mouse he ate both believe Wave has everything focused on winning that key VSC/ERAS sale - well almost everything focued on that, they are aparently willing and able to move a fair bit of the Safend-DLP stuff as well, which helps keep the lights on.
The sale coupled with the recent placement heklp the balance sheet, the sale for the moment improves cash-flow. My understanding is balance sheets and cash-flow etc. may be important to potential customers, so any sizable sale is a good thing.
The above content is my opinion.
